Pasithea Therapeutics (KTTA): שווי מצרפי של הפעילות העסקית

Pasithea Therapeutics (KTTA) develops medications to combat severe mental pathologies while minimizing the risks of raw material supply disruptions for testing. This chart confirms a market price of -32.64. The company protects its early-stage developments with patents, avoiding price wars in the race for schizophrenia treatments. The business relies on the opening of ketamine centers and the synthesis of new small molecules for the therapy of neurofibromatosis.

Enterprise value reflects the total market price of an asset, combining market capitalization and debt minus liquid assets to assess the actual cost of acquisition. Analyzing the total capital level of Pasithea Therapeutics (KTTA) allows for a comparison of its financial stability against the resources of pharma behemoths, which is critical given the high risks and fierce competition involved in developing treatments for neurological pathologies.